Hongjiang Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hongjiang Wu has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
- Andrea On Yan Luk
Department of Medicine and Therapeutics, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China
29 shared publications - Juliana Chung Ngor Chan
Department of Medicine and Therapeutics, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China
27 shared publications - Alice Pik Shan Kong
Department of Medicine and Therapeutics, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China
26 shared publications - Ronald Ching Wan Ma
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region 1 , People’s Republic of China
26 shared publications - Eric Siu Him Lau
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
25 shared publications - Elaine Chow
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
22 shared publications
Latest Publications
- 13 July 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 239, 113433
Healthcare cost trajectories before and after incident cardiovascular disease in type 2 diabetes: A latent class analysis
- 13 July 2026
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 239, 113433
Healthcare cost trajectories before and after incident cardiovascular disease in type 2 diabetes: A latent class analysis
- Open Access
- 5 June 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (9) , 2512-2522
Early glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes
Aims/hypothesis: The aim of this study was to determine whether overall and time-specific patterns of hyperglycaemia, particularly soon after diagnosis, are associated with incident cancer in adults with newly diagnosed type 2 diabetes. Methods: We retrospectively analysed a territory-wide cohort of 52,926 Hong Kong Chinese people with newly diagnosed type 2 diabetes. We examined cancer risk across groups of individuals classified according to their time-weighted mean HbA 1c over the entire follow-up period ( n =49,978) or during specific early exposure periods ( n =39,185). A weighted cumulative exposure model was used to determine the role of historical HbA 1c exposures in cancer development ( n =49,966). Results: Among 49,978 individuals with newly diagnosed type 2 diabetes, 1758 cancer events occurred. Each 11 mmol/mol (1%) increase in time-weighted mean HbA 1c was associated with a 27% relative higher risk of cancer at any site (HR 1.27; 95% CI 1.20, 1.33). Within the first 2 years after diagnosis, a time-weighted mean HbA 1c ≥53 mmol/mol (≥7.0%) vs 1c category, even after adjusting for subsequent HbA 1c . Longer durations of early exposure were associated with higher risk, reaching 51–213% in the first 5 years of exposure. Earlier high HbA 1c exposures contributed more strongly to cancer risk than later exposures. A 11 mmol/mol (1%) HbA 1c reduction at 1–2 years was associated with a 6% relative lower cancer risk over a hypothetical 10 year window (HR 0.94; 95% CI 0.91, 0.98), whereas reductions after 5 years showed no significant risk differences. Conclusions/interpretation: Overall, hyperglycaemic exposure was associated with an elevated long-term cancer risk in type 2 diabetes. Notably, individuals who showed better glycaemic management soon after diagnosis exhibited a lower cancer risk than those whose glycaemic management improved later, despite comparable overall glycaemic burdens.
- 5 June 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (9) , 2512-2522
Open AccessEarly glycaemic exposure and cancer risk in people with newly diagnosed type 2 diabetes
Aims/hypothesis: The aim of this study was to determine whether overall and time-specific patterns of hyperglycaemia, particularly soon after diagnosis, are associated with incident cancer in adults with newly diagnosed type 2 diabetes. Methods: We retrospectively analysed a territory-wide cohort of 52,926 Hong Kong Chinese people with newly diagnosed type 2 diabetes. We examined cancer risk across groups of individuals classified according to their time-weighted mean HbA 1c over the entire follow-up period ( n =49,978) or during specific early exposure periods ( n =39,185). A weighted cumulative exposure model was used to determine the role of historical HbA 1c exposures in cancer development ( n =49,966). Results: Among 49,978 individuals with newly diagnosed type 2 diabetes, 1758 cancer events occurred. Each 11 mmol/mol (1%) increase in time-weighted mean HbA 1c was associated with a 27% relative higher risk of cancer at any site (HR 1.27; 95% CI 1.20, 1.33). Within the first 2 years after diagnosis, a time-weighted mean HbA 1c ≥53 mmol/mol (≥7.0%) vs 1c category, even after adjusting for subsequent HbA 1c . Longer durations of early exposure were associated with higher risk, reaching 51–213% in the first 5 years of exposure. Earlier high HbA 1c exposures contributed more strongly to cancer risk than later exposures. A 11 mmol/mol (1%) HbA 1c reduction at 1–2 years was associated with a 6% relative lower cancer risk over a hypothetical 10 year window (HR 0.94; 95% CI 0.91, 0.98), whereas reductions after 5 years showed no significant risk differences. Conclusions/interpretation: Overall, hyperglycaemic exposure was associated with an elevated long-term cancer risk in type 2 diabetes. Notably, individuals who showed better glycaemic management soon after diagnosis exhibited a lower cancer risk than those whose glycaemic management improved later, despite comparable overall glycaemic burdens.
- Open Access
- 28 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6467-6470
Young People With Type 2 Diabetes Are Under‐Represented in Randomized Clinical Trials
- 28 May 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 6467-6470
Open AccessYoung People With Type 2 Diabetes Are Under‐Represented in Randomized Clinical Trials
- Open Access
- 18 March 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 1792-1805
Differential healthcare costs in individuals with type 2 diabetes and incident chronic kidney disease in Hong Kong: a latent class trajectory analysis
Aims/hypothesis: Chronic kidney disease (CKD) represents a major and costly comorbidity in type 2 diabetes management. Identifying individuals with high healthcare costs due to CKD will support decision-making for early intervention. We used latent class analysis (LCA) to classify Chinese individuals with type 2 diabetes and incident CKD based on their demographic and clinical profiles. Methods: For this study, 2886 individuals with type 2 diabetes and incident CKD and complete data for 42 attributes were selected from the prospective Hong Kong Diabetes Register cohort (2007–2019). We used LCA to select 14 variables to classify participants, followed by a hierarchical generalised linear mixed model to evaluate longitudinal healthcare costs among class memberships. Results: During 109,784 person-years of follow-up, the incidence of CKD was 26.29 per 1000 person-years with a per-patient-per-year (PPPY) cost of US$4395 ± 11,947 (mean ± standard deviation). The four distinct classes used in the LCA based on baseline profiles were as follows: Class 1 (18.3%; PPPY: US$6087 ± 15,519), namely those who were young at onset (44.4 ± 10.3 years), had moderate comorbidities (25.6% had a moderate or high score on the Elixhauser Comorbidity Index [ECI]) and used multiple medications (90.2% used at least three medications); Class 2 (21.2%; PPPY: US$3822 ± 9816), namely those who had old-age onset (66.9 ± 6.9 years), had moderate comorbidities (27.8% had a moderate or high ECI score) and used multiple medications (70.7% used at least three medications); Class 3 (33.9%; PPPY: US$4260 ± 11,725), namely those who were middle-aged at onset (54.2 ± 10.0 years), had few comorbidities (14.0% had a moderate or high ECI score) and used few medications (15.6% used at least three medications); and Class 4 (26.5%; PPPY: US$3923 ± 10,957), namely those who were middle-aged at onset (54.1 ± 7.6 years), had moderate comorbidities (25.3% had a moderate or high ECI score) and used multiple medications (98.9% used at least three medications). Class 1 (young onset) and Class 3 (middle-aged onset) incurred the highest cost during the year of CKD onset, with those in Class 1 having more comorbidities than those in Class 3 at baseline. Multiple healthcare services contributed to the high healthcare costs in Class 1, with costs in Class 3 attributed mainly to post-CKD outpatient and psychiatric care. Conclusions/interpretation: Those with young-onset type 2 diabetes incurred the highest cost during the year of CKD onset. Individuals with middle-aged onset type 2 diabetes with fewer comorbidities and less intensified treatment at baseline also had subsequent increased healthcare costs.
- 18 March 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (7) , 1792-1805
Open AccessDifferential healthcare costs in individuals with type 2 diabetes and incident chronic kidney disease in Hong Kong: a latent class trajectory analysis
Aims/hypothesis: Chronic kidney disease (CKD) represents a major and costly comorbidity in type 2 diabetes management. Identifying individuals with high healthcare costs due to CKD will support decision-making for early intervention. We used latent class analysis (LCA) to classify Chinese individuals with type 2 diabetes and incident CKD based on their demographic and clinical profiles. Methods: For this study, 2886 individuals with type 2 diabetes and incident CKD and complete data for 42 attributes were selected from the prospective Hong Kong Diabetes Register cohort (2007–2019). We used LCA to select 14 variables to classify participants, followed by a hierarchical generalised linear mixed model to evaluate longitudinal healthcare costs among class memberships. Results: During 109,784 person-years of follow-up, the incidence of CKD was 26.29 per 1000 person-years with a per-patient-per-year (PPPY) cost of US$4395 ± 11,947 (mean ± standard deviation). The four distinct classes used in the LCA based on baseline profiles were as follows: Class 1 (18.3%; PPPY: US$6087 ± 15,519), namely those who were young at onset (44.4 ± 10.3 years), had moderate comorbidities (25.6% had a moderate or high score on the Elixhauser Comorbidity Index [ECI]) and used multiple medications (90.2% used at least three medications); Class 2 (21.2%; PPPY: US$3822 ± 9816), namely those who had old-age onset (66.9 ± 6.9 years), had moderate comorbidities (27.8% had a moderate or high ECI score) and used multiple medications (70.7% used at least three medications); Class 3 (33.9%; PPPY: US$4260 ± 11,725), namely those who were middle-aged at onset (54.2 ± 10.0 years), had few comorbidities (14.0% had a moderate or high ECI score) and used few medications (15.6% used at least three medications); and Class 4 (26.5%; PPPY: US$3923 ± 10,957), namely those who were middle-aged at onset (54.1 ± 7.6 years), had moderate comorbidities (25.3% had a moderate or high ECI score) and used multiple medications (98.9% used at least three medications). Class 1 (young onset) and Class 3 (middle-aged onset) incurred the highest cost during the year of CKD onset, with those in Class 1 having more comorbidities than those in Class 3 at baseline. Multiple healthcare services contributed to the high healthcare costs in Class 1, with costs in Class 3 attributed mainly to post-CKD outpatient and psychiatric care. Conclusions/interpretation: Those with young-onset type 2 diabetes incurred the highest cost during the year of CKD onset. Individuals with middle-aged onset type 2 diabetes with fewer comorbidities and less intensified treatment at baseline also had subsequent increased healthcare costs.
- Open Access
- 19 December 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China
- 19 December 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 91
Open AccessComparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China
- 19 November 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113000
Disparities of adiposity explained ethnic differences in insulin sensitivity and secretion traits in adolescents with normoglycaemia
- 19 November 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113000
Disparities of adiposity explained ethnic differences in insulin sensitivity and secretion traits in adolescents with normoglycaemia
- 23 June 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (9) , 1635-1642
Subclasses of Glucose Trajectories in Early Childhood Stratified the Risk of Abnormal Glucose Tolerance in Adolescence and Young Adulthood
Early-life exposures may shape long-term effects on glucose regulation. This study aimed to stratify long-term abnormal glucose tolerance (AGT) risk from early childhood. A total of 906 children were enrolled at baseline and reevaluated in adolescence and young adulthood. By using the latent class trajectory analysis, glucose trajectories of children were measured via five–time point oral glucose tolerance tests and then grouped into three latent subclasses: mild excursion–normal reversion (MN), moderate excursion–delayed reversion (MD), and severe excursion–delayed reversion (SD). Logistic regression was performed to estimate the risk of AGT and associations between cardiometabolic factors and subclasses. In adolescence, compared with the MN subclass, the risk of AGT was 1.7-fold in the MD subclass and 5.5-fold in the SD subclass, after adjusting for age, sex, BMI, and Tanner stage. In young adulthood, the adjusted risk of AGT was 3.6-fold and 11.6-fold in the MD and SD subclasses, respectively. During the full natural history of glucose tolerance, the risk of AGT was 3.6-fold in the MD subclass and 18.1-fold in the SD subclass, after adjusting for childhood covariates. MD and SD subclass membership was strongly associated with childhood hypertension, maternal gestational diabetes, and maternal hypertension during pregnancy. Glucose trajectory subclasses in early childhood effectively stratified the long-term risk of AGT. The association between maternal cardiometabolic health and childhood subclass membership highlighted that prenatal exposures may influence metabolic outcomes in offspring. ARTICLE HIGHLIGHTS: Abnormal glucose tolerance (AGT) in youth has become an alarming global public health issue; however, approaches to identify high-risk population among young people have not been well-established. Can the long-term risk of AGT be stratified by the subclasses of glucose trajectories defined in childhood? Subclasses defined in childhood can efficiently stratify the risk of AGT in adolescence and young adulthood. The subclass membership was strongly associated with cardiometabolic disorders in childhood and maternal cardiometabolic disorders during pregnancy. This subclass method provides a potential strategy to identify those at risk of later cardiometabolic disorders from childhood for more intensive evaluation of intervention. The close relationship between maternal cardiometabolic disorders and subclass membership of children highlighted the potential influence of gestational cardiometabolic health on the development of cardiometabolic disorders in offspring.
- 23 June 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (9) , 1635-1642
Subclasses of Glucose Trajectories in Early Childhood Stratified the Risk of Abnormal Glucose Tolerance in Adolescence and Young Adulthood
Early-life exposures may shape long-term effects on glucose regulation. This study aimed to stratify long-term abnormal glucose tolerance (AGT) risk from early childhood. A total of 906 children were enrolled at baseline and reevaluated in adolescence and young adulthood. By using the latent class trajectory analysis, glucose trajectories of children were measured via five–time point oral glucose tolerance tests and then grouped into three latent subclasses: mild excursion–normal reversion (MN), moderate excursion–delayed reversion (MD), and severe excursion–delayed reversion (SD). Logistic regression was performed to estimate the risk of AGT and associations between cardiometabolic factors and subclasses. In adolescence, compared with the MN subclass, the risk of AGT was 1.7-fold in the MD subclass and 5.5-fold in the SD subclass, after adjusting for age, sex, BMI, and Tanner stage. In young adulthood, the adjusted risk of AGT was 3.6-fold and 11.6-fold in the MD and SD subclasses, respectively. During the full natural history of glucose tolerance, the risk of AGT was 3.6-fold in the MD subclass and 18.1-fold in the SD subclass, after adjusting for childhood covariates. MD and SD subclass membership was strongly associated with childhood hypertension, maternal gestational diabetes, and maternal hypertension during pregnancy. Glucose trajectory subclasses in early childhood effectively stratified the long-term risk of AGT. The association between maternal cardiometabolic health and childhood subclass membership highlighted that prenatal exposures may influence metabolic outcomes in offspring. ARTICLE HIGHLIGHTS: Abnormal glucose tolerance (AGT) in youth has become an alarming global public health issue; however, approaches to identify high-risk population among young people have not been well-established. Can the long-term risk of AGT be stratified by the subclasses of glucose trajectories defined in childhood? Subclasses defined in childhood can efficiently stratify the risk of AGT in adolescence and young adulthood. The subclass membership was strongly associated with cardiometabolic disorders in childhood and maternal cardiometabolic disorders during pregnancy. This subclass method provides a potential strategy to identify those at risk of later cardiometabolic disorders from childhood for more intensive evaluation of intervention. The close relationship between maternal cardiometabolic disorders and subclass membership of children highlighted the potential influence of gestational cardiometabolic health on the development of cardiometabolic disorders in offspring.
- Open Access
- 5 June 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 59, 101585
Population-level productivity-adjusted life years lost in individuals with type 2 diabetes in Hong Kong: a life table modelling study
- 5 June 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 59, 101585
Open AccessPopulation-level productivity-adjusted life years lost in individuals with type 2 diabetes in Hong Kong: a life table modelling study
- 9 May 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (4) , 101660
Global Burden of type 2 diabetes in non-elderly individuals 1990 to 2021 and projections for 2050: a systematic analysis of the 2021 Global Burden of Disease
- 9 May 2025
- Published by Elsevier in Diabetes & Metabolism
- Vol. 51 (4) , 101660
Global Burden of type 2 diabetes in non-elderly individuals 1990 to 2021 and projections for 2050: a systematic analysis of the 2021 Global Burden of Disease